Prostate-specific antigen: Its usefulness in clinical medicine

Trends in Endocrinology and Metabolism

Volumn 9, Issue 8, 1998, Pages 310-316

  Diamandis, Eleftherios P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF ONTARIO INSTITUTE OF TECHNOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; MEMBRANE ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

BREAST CARCINOMA; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION REGULATION; GENE THERAPY; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROSTATECTOMY; REVIEW;

EID: 0031656568     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(98)00082-4     Document Type: Review

References (49)

1. Armbruster DA Prostate-specific antigen: biochemistry, analytical methods, and clinical application. Clin Chem. 39:1993;181-195.
2. Borchert G, Giai M, Diamandis EP Elevated levels of prostate specific antigen in serum of women with fibroadenomas and breast cysts. J Natl Cancer Inst. 89:1997;587-588.
3. Brawer MK, Beatie J, Wener MH, Vessella RL, Preston SD, Lange PH Screening for prostate carcinoma with prostate specific antigen: results of the second year. J Urol. 150:1993;106-109.
4. Cadeddu JA, Partin AW, DeWeese TL, Walsh PC Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol. 159:1998;173-177.
5. Catalona WJ, Smith DS, Ratliff TL, Basler JW Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 270:1993;948-954.
6. Chan JM, Stampfer MJ, Giovannucci Eet al. Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science. 279:1998;563-565.
7. Chu TM Prostate-specific antigen and early detection of prostate cancer. Tumor Biol. 18:1997;123-134.
8. Cleutjens KBJM, van der Korput HAGM, Ehren-van Eekelen CCet al. A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. Mol Endocrinol. 11:1997;1256-1265.
9. Cleutjens KBJM, van der Korput HAGM, van Eekelen CCEM, van Rooji HCJ, Feber PW, Trapman J An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol. 11:1997;148-161.
10. Corey E, Wegner SK, Corey MJ, Vessella RL Prostate-specific antigen: characterization of epitopes by synthetic peptide mapping and inhibition studies. Clin Chem. 43:1997;575-584.
11. Corey F, Arfman EW, Liu AY, Vessella RL Improved reverse transcriptase-polymerase chain reaction protocol with exogenous internal competitive control for prostate-specific antigen mRNA in blood and bone marrow. Clin Chem. 43:1997;443-452.
12. Cox J, Grignon DJ, Kaplan RSet al. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
13. Deguchi T, Doi T, Ehara H, Ito Set al. Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res. 53:1993;5350-5354.
14. Deguchi T, Muzheng Y, Kawada Y Micrometastasis of prostate cancer to lymph nodes: detection by means of reverse transcription-polymerase chain reaction. J Natl Cancer Inst. 89:1997;1471-1473.
15. Diamandis EP Clinical application of ultrasensitive prostate specific antigen assays. J Natl Cancer Inst. 89:1997;1077.
16. Diamandis EP Prostate-specific antigen or human kallikrein 3? Tumor Biol. 19:1998;65-68.
17. Diamandis EP, Yu H New biological functions of prostate specific antigen? J Clin Endocrinol Metab. 80:1995;1515-1517.
18. Diamandis EP, Yu H Prostate cancer, prostate specific antigen and polymerase chain reaction. Clin Chem. 41:1995;177-179.
19. Ellis WJ, Vessella RL, Noteboon JLet al. Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay. Urology. 50:1997;573-579.
20. Ferguson RA, Yu H, Kalyvas M, Zammit S, Diamandis EP Ultrasensitive detection of prostate specific antigen by a time-resolved immunofluorometric assay and the Immulite® immunochemiluminescent third generation assay: potential applications in prostate and breast cancers. Clin Chem. 42:1996;675-684.
21. Graves HCB, Kamarei M, Stamey TA Identity of prostate specific antigen and the semen protein Pp30 purified by a rapid chromatography technique. J Urol. 144:1990;1510-1515.
22. Gregorakis AK, Holmes EH, Murphy GP Prostate-specific membrane antigen: current and future utility. Semin Urol Oncol. 16:1998;2-12.
23. Hara M, Koyanagi Y, Inoue T, Fukuyama T Some physicochemical characteristics of gamma-seminoprotein; an antigenic component specific for human seminal plasma. Jpn J Legal Med. 25:1971;322-324.
24. Li TS, Beling CG Isolation and characterization of two specific antigens of human seminal plasma. Fertil Steril. 24:1973;134-143.
25. Lilja H Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest. 80:1987;281-285.
26. Lilja H, Christensson A, Dahlen Uet al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 37:1991;1618-1625.
27. Lopez-Otin C, Diamandis EP: Breast and prostate cancer: an analysis of common epidemiologic, genetic and biochemical features. Endocr Rev (in press).
28. McCormack RT, Rittenhouse HG, Finlay JAet al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology. 45:1995;729-744.
29. Melegos D, Diamandis EP Diagnostic value of molecular forms of prostate specific antigen for female breast cancer. Clin Biochem. 29:1996;193-200.
30. Mikolajczyk SD, Grauer LS, Millar LSet al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology. 50:1997;710-714.
31. Narayan P, Gajendran V, Taylor SPet al. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology. 46:1995;205.
32. Oesterling JE, Martin SK, Bergstralh EJet al. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA. 269:1993;57.
33. Patel A, Dorey F, Franklin J, deKernion JB Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 158:1997;1441-1445.
34. Peehl DM Prostate specific antigen role and function. Cancer. 75(Supp):1995;2021-2026.
35. Prestigiacomo A, Stamey T A comparison of 4 ultrasensitive prostate specific antigen assays for early detection of residual cancer after radical prostatectomy. J Urol. 152:1994;1515-1519.
36. Pruthi RS, Johnston I, Tu I-P, Stamey TA Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer. Urology. 49:1997;737-742.
37. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW: Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci (in press).
38. Sauter ER, Daly M, Lenahan Ket al. Prostate specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. Cancer Epidemiol Biomarkers Prevent. 5:1996;967-970.
39. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson DR Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem. 271:1996;7043-7051.
40. Sensabaugh GF Isolation and characterization of a semen-specific protein from human seminal plasma: a potential new marker for semen identification. J Forensic Sci. 23:1978;106-115.
41. Stamey TA Some comments on progress in the standardization of immunoassays for prostate-specific antigen. Br J Urol. 79:1997;49-52.
42. Stenman UH, Leinonen J, Alfthan Het al. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 51:1991;222-226.
43. Wang MC, Valenzuela LA, Murphy GP, Chu TM Purification of a human prostate specific antigen. Invest Urol. 17:1979;159-163.
44. Wang TJ, Linton HJ, Sokoloff RL, et al.: Antibody specificities for PSA and PSA fragments by SDS-PAGE western blot analysis. Tumor Biol (in press).
45. Witherspoon LR, Lapeyrolerie T Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy. J Urol. 157:1997;1322-1328.
46. Yu H, Giai M, Diamandis EP, Katsaros Det al. Prostate specific antigen is a new favourable prognostic indicator for women with breast cancer. Cancer Res. 55:1995;2104-2110.
47. Yu H, Diamandis EP, Wong P-Y, Nam R, Trachtenberg J Detection of prostate cancer relapse with prostate specific antigen monitoring at levels between 0.001-0.1 μg/L. J Urol. 157:1997;913-918.
48. Zarghami N, Grass L, Diamandis EP Steroid hormone regulation of prostate specific antigen gene expression in breast cancer. Br J Cancer. 75:1997;579-588.
49. Zhang WM, Leinonen J, Kalkkinen Net al. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem. 41:1995;1567-1573.